Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.

Saved in:
Bibliographic Details
Title: Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
Authors: Short NJ; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Daver NG; University of Texas, MD Anderson Cancer Center, Houston, Texas, United States., Azevedo RS; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Karrar O; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., DiNardo CD; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Kadia TM; MD Anderson Cancer Center, Houston, Texas, United States., Yilmaz M; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Maroun MM; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Hachem MCR; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Borthakur G; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Issa GC; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Shpall EJ; MD Anderson, Houston, Texas, United States., Popat UR; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Huang X; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Qiao W; MD Anderson Cancer Center, Houston, Texas, United States., Nasr LF; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Macaron W; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Abramova R; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Garcia-Manero G; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Konopleva M; Albert Einstein College of Medicine, New York, New York, United States., Ravandi F; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States.
Source: Blood advances [Blood Adv] 2026 May 27. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2026019841